Osteonic Begins Exporting Sports Medicine Products to the U.S. Through Zimmer Biomet

Osteonic, a company specializing in orthopedic implants, announced on May 12, 2025, that it has begun exporting its Sports Medicine products to the United States following FDA approval granted in December of last year.

This export to the United States is part of Osteonic’s global OEM/ODM supply agreement with its partner Zimmer Biomet. The products will be supplied under the Zimmer Biomet brand and sold in the U.S. orthopedic market.

In 2020, Osteonic signed an exclusive global supply agreement to provide Sports Medicine products to Zimmer Biomet, the world’s second-largest orthopedic medical device company. Through this agreement, Zimmer Biomet was able to strengthen its Sports Medicine product lineup and secure price competitiveness, while Osteonic secured a stable global revenue source. The fact that Osteonic’s technology and product competitiveness were recognized by Zimmer Biomet, the world’s second-largest company in the field, attracted significant attention in the market.

Osteonic has recently been supplying its products to Europe, Australia, Japan, and India through Zimmer Biomet, and now adds the United States, the largest market, to its export destinations. According to Data Bridge Market Research (2023) and statistics from the Korea Health Industry Development Institute, the global Sports Medicine market was estimated at 7.2 trillion won in 2022, with the U.S. market accounting for 3.4 trillion won.

The Sports Medicine product line from Osteonic, which recently received FDA approval, is used in surgeries to fix ligament tissue to bone when ligament injuries occur in various joints.

These products are made from a proprietary biocomposite material developed by Osteonic, offering both biocompatibility and optimized physical strength and function.

Lee Dongwon, CEO of Osteonic, stated, "With the start of Sports Medicine exports to the United States, we expect rapid and sustained performance growth over the mid- to long-term. In particular, since the supply price to Zimmer Biomet is higher than our domestic sales price, increases in these sales will lead to even greater growth in operating profit. We will achieve even greater performance growth by expanding our export countries and rapidly growing new product lines such as spinal implants, in addition to the existing sales and operating profit growth of over 20% annually."